Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
4 hedge funds and large institutions have $1K invested in Orexigen Therapeutics, Inc. in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 23 closing their positions.
85% less funds holding
Funds holding: 27 → 4 (-23)
100% less capital invested
Capital invested by funds: $689K → $1K (-$688K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 23
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$465K |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$108K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$35K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$18K |
| 5 |
OWIM
Old West Investment Management
Los Angeles,
California
|
-$14K |
OREX Hedge Fund Activity: Q2 2018 in Review
4 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q2 2018, worth a combined $1K — down 100% from $689K a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of OREX and 0 opened new positions — a net loss of 23 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Baupost Group, exiting entirely with an estimated $465K sold.
- 4 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q2 2018, down from 27 in Q1 2018.
- Funds reported $1K of Orexigen Therapeutics, Inc. stock for Q2 2018, down 100% quarter-over-quarter.
- 0 funds opened new Orexigen Therapeutics, Inc. positions in Q2 2018 and 23 closed out, a net change of -23 holders.
- The largest Orexigen Therapeutics, Inc. seller in Q2 2018 was Baupost Group, an estimated $465K sold.
Based on aggregated 13F filings for Q2 2018.